Changzhou Qianhong Biopharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021
August 20, 2021 at 01:35 pm IST
Share
Changzhou Qianhong Biopharma CO.,LTD announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 873.009 million compared to CNY 654.688 million a year ago. Operating income was CNY 108.234 million compared to CNY 82.999 million a year ago. Net income was CNY 89.150 million compared to CNY 63.706 million a year ago. Basic earnings per share from continuing operations was CNY 0.0715 compared to CNY 0.0528 a year ago.
Changzhou Qianhong Biopharma CO., LTD is a China-based company, principally engaged in the research and development, production and distribution of freeze-drying powder, freeze-drying powder injections, small volume injections, tablets, hard capsules, granules and bulk drugs, among others. The Company mainly provides liquaemin sodium raw materials and preparations, applied to prevent and treat thromboembolism desease; kallidinogen preparations, applied in the treatment of micro-circulation disorder disease, asparaginase bulk drugs and preparations, applied in the treatment of acute lymphoblastic leukemia, as well as compound digestive enzyme capsules II. The Company distributes its products within domestic market and to overseas markets.
CHANGZHOU QIANHONG BIOPHARMA CO.,LTD 
